Arvinas, Inc.
A biotech company pioneering a new kind of medicine that works like a cellular "molecular matchmaker": instead of blocking disease-causing proteins, its PROTAC drugs tag them for the cell's own garbage disposal (the proteasome) to shred and recycle. Founded in 2013 by Yale professor Craig Crews, Arvinas grew out of his earlier company Proteolix, and in 2026 its breast-cancer therapy vepdegestrant, developed with Pfizer, became the first FDA-approved PROTAC treatment. It focuses on cancer and neurological disease.
Sold 1.36M
Bought 1.00M
Granted 12.9K · Bought 15.0K · Sold 400.0K
Bought 312.5K
Granted 608.6K · Bought 30.0K · Sold 271.8K
Bought 312.5K
Granted 24.9K · Bought 1.82M · Sold 662.1K
Granted 160.5K · Sold 21.1K
Granted 223.3K · Sold 31.9K
Granted 215.1K · Sold 27.7K
Granted 147.0K · Bought 1.6K · Sold 139.9K
Granted 169.7K · Sold 27.2K
Granted 206.0K · Bought 1.0K · Sold 129.4K
Granted 73.9K · Bought 52.5K · Sold 41.9K
Granted 41.6K · Bought 29.3K
Granted 134.4K · Sold 66.9K
Bought 40.0K · Sold 80.8K
Granted 41.6K
Granted 41.6K
Granted 41.6K
Granted 41.6K
Granted 40.6K · Sold 5.9K
Granted 30.2K
Granted 26.0K
Granted 4.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Diekman John D +5 co-filers10% owner · 22 transactions | — | 6.94Mas of Sep 2019 | — | — | 1.36M |
| Canaan IX L.P. +1 co-filer10% owner · 4 transactions | — | 3.59Mas of Oct 2020 | — | — | — |
| Kolchinsky Peter +2 co-filersFormer 10% Owner · 3 transactions | — | 1.85Mas of Oct 2018 | — | 1.00M | — |
| Shannon Timothy MDirector · 32 transactions | — | 1.76Mas of Sep 2021 | 12.9K | 15.0K | 400.0K |
| Loven JakobDirector · 2 transactions | — | 1.69Mas of Oct 2018 | — | 312.5K | — |
| Houston John GDirector · 47 transactions | — | 1.12M | 608.6K | 30.0K | 271.8K |
| Deerfield Management Company, L.P. (Series C) +7 co-filersReporting owner · 6 transactions | — | 1.03Mas of Oct 2018 | — | 312.5K | — |
| Ratcliffe LiamDirector · 48 transactions | — | 914.2Kas of Dec 2021 | 24.9K | 1.82M | 662.1K |
| Bettigole Robert A. +2 co-filersFormer 10% owner · 1 transaction | — | 767.6Kas of Oct 2018 | — | — | — |
| Teel RandyPresident and CEO, Director · 7 transactions | — | 285.0K | 160.5K | — | 21.1K |
| Berkowitz NoahChief Medical Officer · 8 transactions | — | 191.4K | 223.3K | — | 31.9K |
| Saik AndrewChief Financial Officer · 8 transactions | — | 187.4K | 215.1K | — | 27.7K |
| Cassidy Sean AChief Financial Officer · 44 transactions | — | 181.9Kas of Feb 2024 | 147.0K | 1.6K | 139.9K |
| Cacace Angela MChief Scientific Officer · 12 transactions | — | 180.4K | 169.7K | — | 27.2K |
| Taylor IanPresident, R&D · 45 transactions | — | 160.8Kas of Feb 2025 | 206.0K | 1.0K | 129.4K |
| Morrison BriggsDirector · 16 transactions | — | 111.5K | 73.9K | 52.5K | 41.9K |
| Kennedy Edward Moore Jr.Director · 7 transactions | — | 84.3K | 41.6K | 29.3K | — |
| Peck RonaldChief Medical Officer · 19 transactions | — | 67.5Kas of Feb 2024 | 134.4K | — | 66.9K |
| Margus Bradley AlbertDirector · 7 transactions | — | 61.5Kas of Aug 2021 | — | 40.0K | 80.8K |
| Bain LindaDirector · 4 transactions | — | 41.6K | 41.6K | — | — |
| Cunningham EverettDirector · 4 transactions | — | 41.6K | 41.6K | — | — |
| Norwalk Leslie VDirector · 4 transactions | — | 41.6K | 41.6K | — | — |
| Smaldone Alsup LaurieDirector · 4 transactions | — | 41.6K | 41.6K | — | — |
| Loomis David KVP, Chief Accounting Officer · 11 transactions | — | 40.2K | 40.6K | — | 5.9K |
| Agarwal SunilDirector · 3 transactions | — | 30.2Kas of Jun 2025 | 30.2K | — | — |
| Young John DDirector · 3 transactions | — | 26.0Kas of Jun 2025 | 26.0K | — | — |
| Dixon Wendy LDirector · 1 transaction | — | 9.1Kas of Jun 2023 | 4.1K | — | — |
| Parmar KushDirector · 2 transactions | — | 1.8Kas of Sep 2019 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +349.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.